Trial reportBioMed research international2022
Effects of Different Doses of Rimazolam on Oxidative Stress Level Sedation Score and Recovery Time of Patients during Hip Replacement.
Trial report in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Retracted: Effects of Different Doses of Rimazolam on Oxidative Stress Level Sedation Score and Recovery Time of Patients during Hip Replacement.BioMed research international · 2023Article
Corrections and comments
- Retraction · 2023-07-12Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Computer-Aided Content or Computer-Generated Content · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of Rimazolam on oxidative stress level, sedation score, and recovery time of patients under different doses in hip replacement are investigated. A total of 100 patients who underwent hip arthroplasty in our hospital from September 2020 to May 2022 are selected as the study subjects. According to the random number table method, they are divided into observation group and control group. The observation group is given 0.3 mg/kg Rimazolam, and the control group is given 0.4 mg/kg Rimazolam. Oxidative stress level, hemodynamic indexes at different time after anesthesia, sedation score and sedation depth, Visual Analogue Scale/Score (VAS) score and incidence of adverse reactions are observed in 2 groups. The correlation of sedation score with oxidative stress index and pain degree is analyzed. The experimental results show that Rimazolam has a good anesthesia induction effect in hip replacement, but the low dose (0.3 mg/kg) can reduce the level of oxidative stress in patients, has a better sedation effect and can maintain the stability of patients' hemodynamic indicators, and has a positive effect on relieving postoperative pain in patients. [Clinical Trial Registration Number- ChiCTR2000038548].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.